Axon Enterprise, Inc. (NASDAQ:AXON) Shares Bought by Freestone Capital Holdings LLC

Freestone Capital Holdings LLC lifted its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 127.1% in the first quarter, HoldingsChannel reports. The firm owned 2,487 shares of the biotechnology company’s stock after acquiring an additional 1,392 shares during the period. Freestone Capital Holdings LLC’s holdings in Axon Enterprise were worth $778,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AXON. Dynamic Advisor Solutions LLC bought a new position in shares of Axon Enterprise during the fourth quarter worth about $226,000. BKM Wealth Management LLC bought a new position in shares of Axon Enterprise during the fourth quarter worth about $32,000. Brookstone Capital Management bought a new position in shares of Axon Enterprise during the fourth quarter worth about $206,000. HB Wealth Management LLC lifted its position in shares of Axon Enterprise by 3.9% during the fourth quarter. HB Wealth Management LLC now owns 1,139 shares of the biotechnology company’s stock worth $294,000 after purchasing an additional 43 shares during the last quarter. Finally, Raymond James & Associates lifted its position in shares of Axon Enterprise by 32.8% during the fourth quarter. Raymond James & Associates now owns 83,655 shares of the biotechnology company’s stock worth $21,611,000 after purchasing an additional 20,654 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Julie A. Cullivan sold 993 shares of Axon Enterprise stock in a transaction on Friday, May 31st. The shares were sold at an average price of $281.72, for a total value of $279,747.96. Following the transaction, the director now owns 4,553 shares in the company, valued at approximately $1,282,671.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Julie A. Cullivan sold 993 shares of Axon Enterprise stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $281.72, for a total transaction of $279,747.96. Following the sale, the director now directly owns 4,553 shares in the company, valued at approximately $1,282,671.16. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Julie A. Cullivan sold 478 shares of Axon Enterprise stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $286.04, for a total transaction of $136,727.12. Following the sale, the director now owns 5,546 shares in the company, valued at $1,586,377.84. The disclosure for this sale can be found here. Insiders have sold 89,447 shares of company stock worth $27,684,677 in the last quarter. 6.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

AXON has been the topic of several research analyst reports. Bank of America began coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price target on the stock. Craig Hallum raised their price target on shares of Axon Enterprise from $325.00 to $370.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Morgan Stanley raised their price target on shares of Axon Enterprise from $285.00 to $310.00 and gave the company an “equal weight” rating in a research note on Friday, April 26th. Barclays raised their price target on shares of Axon Enterprise from $308.00 to $381.00 and gave the company an “overweight” rating in a research note on Wednesday, May 8th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $375.00 price objective on shares of Axon Enterprise in a report on Tuesday, May 7th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $342.54.

Axon Enterprise Stock Up 0.0 %

Shares of Axon Enterprise stock traded up $0.12 during midday trading on Friday, reaching $310.93. 166,577 shares of the company’s stock traded hands, compared to its average volume of 487,389. The company has a market cap of $23.47 billion, a price-to-earnings ratio of 90.88, a price-to-earnings-growth ratio of 7.06 and a beta of 0.95. The company’s 50 day simple moving average is $294.06 and its 200 day simple moving average is $291.32. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.55 and a current ratio of 2.91. Axon Enterprise, Inc. has a 52 week low of $175.37 and a 52 week high of $329.87.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Friday, May 10th. The biotechnology company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.95 by $0.20. The firm had revenue of $460.74 million for the quarter, compared to the consensus estimate of $441.57 million. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The business’s quarterly revenue was up 34.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.51 EPS. Equities analysts expect that Axon Enterprise, Inc. will post 2.35 earnings per share for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.